MedTrace Logo

MAD Study of NX210c

NCT05827653 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2024-12-13

No results posted yet for this study

Summary

This study will investigate the safety and tolerability of multiple intravenous infusions of NX210c with two ascending doses as well as NX210c pharmacokinetics (PK), and pharmacodynamics (PD) effects in healthy elderly subjects.

Conditions

  • Healthy Elderly

Interventions

DRUG

NX210c

3 times a week, for 28 days

DRUG

Placebo

3 times a week, for 28 days

Sponsors & Collaborators

  • Centre for Human Drug Research, Netherlands

    collaborator OTHER

  • Axoltis Pharma

    lead INDUSTRY

Principal Investigators

  • Philip Kremer, MD, PharmD, PhD · Centre For Human Drug Research

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-05
Primary Completion
2023-04-29
Completion
2023-10-02

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05827653 on ClinicalTrials.gov